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Abstract
Targeted therapeutic approaches are increasingly being implemented in the clinic, but early detection of response
frequently presents a challenge as many new therapies lead to inhibition of tumor growth rather than tumor shrinkage.
Development of novel non-invasive methods to monitor response to treatment is therefore needed. Magnetic resonance
spectroscopy (MRS) and magnetic resonance spectroscopic imaging are non-invasive imaging methods that can be
employed to monitor metabolism, and previous studies indicate that these methods can be useful for monitoring the
metabolic consequences of treatment that are associated with early drug target modulation. However, single-metabolite
biomarkers are often not specific to a particular therapy. Here we used an unbiased 1H MRS-based metabolomics approach
to investigate the overall metabolic consequences of treatment with the phosphoinositide 3-kinase inhibitor LY294002 and
the heat shock protein 90 inhibitor 17AAG in prostate and breast cancer cell lines. LY294002 treatment resulted in
decreased intracellular lactate, alanine fumarate, phosphocholine and glutathione. Following 17AAG treatment, decreased
intracellular lactate, alanine, fumarate and glutamine were also observed but phosphocholine accumulated in every case.
Furthermore, citrate, which is typically observed in normal prostate tissue but not in tumors, increased following 17AAG
treatment in prostate cells. This approach is likely to provide further information about the complex interactions between
signaling and metabolic pathways. It also highlights the potential of MRS-based metabolomics to identify metabolic
signatures that can specifically inform on molecular drug action.
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Introduction
The Warburg effect, wherein cancer cells have an abnormally
elevated rate of glucose consumption and aerobic glycolysis, was
first discovered in the 1920s [1]. Research over the past decade is
increasingly demonstrating that several other aspects of metabo-
lism are also profoundly different in cancer cells [2,3]. Many of
these changes appear to result from the acquisition of mutations
that develop during oncogenesis and provide a growth advantage
to the cancerous cells in the tumor microenvironment. Knowledge
of these metabolic changes is now being used as the basis for
development of more specific molecular imaging methods. For
instance, the higher glycolytic demand characterizing cancer cells
has been exploited in [18F] 2-fluoro-2-deoxy-D-glucose positron
emission tomography (FDG-PET) imaging of tumors [4]. In recent
years, owing to advances in dynamic nuclear polarization (DNP),
the elevated glycolytic rates in tumors have also been imaged using
13C magnetic resonance spectroscopy (MRS) by probing the
conversion of hyperpolarized pyruvate into lactate [5–7]. Con-
versely, several reports have been published reporting normaliza-
tion of glucose metabolism as an indication of response to targeted
treatment [8,9]. A decrease in pyruvate to lactate conversion in
response to treatment with phosphoinositide 3-kinase (PI3K) or
receptor tyrosine kinase (RTK) inhibitors was shown in different
tumor types by 13C MRS [10,11]. Phosphocholine (PC) or,
clinically, total choline (tCho, comprised of choline, PC and
glycerophosphocholine) was also identified in several MR studies
as an important biomarker that is generally elevated in cancer cells
and associated with more aggressive and invasive phenotypes [12–
20]. Inhibition of cell proliferation following treatment with
targeted therapies, including inhibitors of Ras, PI3K, mitogen-
activated protein kinases (MAPK) and hypoxia inducible factor
(HIF) led in most cases to a drop in PC and tCho [21–31]. In
particular, inhibition of HIF-1a with PX-478 in HT-29 colorectal
cancer xenografts induced a drop in intracellular PC levels as well
as tCho [26]. Pharmacological intervention with the PI3K
inhibitor PI-103 induced a drop in PC in PC3 prostate cancer
cells and HCT116 colorectal cancer cells [21]. Similarly in MDA-
MB-231, MCF-7 and Hs578T breast cancer cells treated with
either LY294002 or Wortmannin PC dropped [22]. Finally
orthotopic glioblastoma tumors treated with the PI3K inhibitor
PX-886 also lead to a drop in tCho [31]. Interestingly, treatment
with the heat shock protein (HSP) 90 inhibitor 17-(Allylamino)-17-
demethoxygeldanamycin (17AAG), which likely has a more
complex effect on cellular signaling as it targets a number of
protein kinases (including Akt, MEK and c-Raf) as well as
hormone receptors [32], was reported to cause an increase in PC
in several cancer models including breast and colorectal [24,25].
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However, treatment with 17AAG in prostate cancer xenografts in
mice (hormone sensitive CWR22 and hormone resistant CWR22r)
induced a drop in the tCho pool [27]. While demonstrating the
value of metabolic changes as biomarkers of response to targeted
therapies, these studies also highlight the fact that some metabolic
changes are common to different therapeutic agents. An
alternative approach is the use of completely untargeted and
global metabolic profiling methods coupled with a robust
chemometric analysis based on multivariate statistical methods
of analysis. These approaches have been proposed for the
detection and identification of global metabolic changes in human
biofluids as a diagnostic tool [33–35]. Similar approaches have
also been employed in cell model systems to investigate the
metabolic effects of drug treatments or different genetic pheno-
types [36–38]. Recently this approach was also used in studies of
tumor biopsy samples providing a method to distinguish between
normal and malignant tissue in different cancer types [39–43].
Due to the completely untargeted nature of these studies and the
size and complexity of the metabolic signature datasets, the
application of appropriate multivariate statistical methods of
analysis is key to identifying the most prominent changes in the
metabolic signature. In cell model systems principal component
analysis (PCA) is usually appropriate to efficiently identify and
discriminate the underlying metabolic variation in the datasets.
Moreover, PCA is a completely unsupervised method and does not
require any a priori information about the data allowing for a
completely unbiased analysis of the datasets [44].
Several PI3K inhibitors are currently in clinical trials for cancer
treatment [45]. Similarly, the HSP90 inhibitor 17AAG has been
tested in the clinic for treatment of solid tumors [46,47]. We were
therefore interested in assessing the individual signatures of
response that could potentially be translated into the clinic. In
this study, we investigated two prostate cancer cell lines, PC3 and
LNCaP, and used an untargeted and unbiased 1H MRS-based
metabolomics approach to investigate the metabolic consequences
of pharmacological inhibition of the PI3K signaling pathway and
the HSP90 protein chaperone using LY294002 and 17AAG,
respectively. Moreover, to confirm the generality of our findings,
we investigated the metabolic changes induced by LY294002 and
17AAG in MCF-7 breast cancer cells. Based on the analysis of the
comprehensive changes in the metabolome of these cell lines we
identified a pattern of metabolic changes that was different for
each of the two drugs but identical for the three different cell lines.
This approach could provide drug-specific metabolic readouts of
molecular drug action. Furthermore, this method could be used to
identify previously unrecognized metabolic changes associated
with modulation of specific signaling pathways.
Results
Treatment doses and target inhibition in prostate cancer
cell lines
Two prostate cancer cell lines, PC3 and LNCaP, were treated
for 48 hours with LY294002, a PI3K inhibitor, and 17AAG, a
HSP90 inhibitor. For each cell line, the treatment doses were
determined such that the cell viability remained approximately
constant during treatment (simulating tumor stasis during
treatment, as opposed to the control cells which proliferate
normally). These doses were 25 mM and 10 mM LY294002, and
1 mM and 0.25 mM 17AAG for PC3 and LNCaP prostate cancer
cells, respectively. Inhibition of the target proteins at the
determined doses was confirmed by Western blotting. Following
48 hours of treatment with LY294002, inhibition of the PI3K
signaling pathway was confirmed in both PC3 and LNCaP cells by
probing for p-4E-BP1 protein levels, which decreased following
treatment (Fig. 1). The effectiveness of the 48 hours 17AAG
treatment was verified by probing the levels of the HSP90-client
protein c-Raf, which decreased in both cell lines (Fig. 1).
Moreover, following 17AAG treatment, p-4E-BP1 decreased to
intermediate levels between the control and LY294002 treated
samples (Fig. 1).
Proton MRS-based metabolomics analysis in prostate
cancer cells
1H MR spectra were recorded on the polar fraction of the cell
extracts (8 replicates per treatment per cell line) of PC3 and
LNCaP prostate cancer cells. To investigate the effect of
treatment on the metabolome of the two prostate cancer cell
lines we performed multivariate statistical analysis on the
complete MRS datasets either including both cell lines and all
the treatment conditions or considering each individual cell line.
The scores plots obtained from the analysis (Fig. 2) clearly
highlight that, as expected, the two cell lines have extremely
different phenotypes (more than 90% of the total variability is
explained by the first principal component in Fig. 2A, segregat-
ing the two cell lines). Moreover, the scores plots obtained from
the PCAs performed on the individual cell lines (Fig. 2B–C)
demonstrate excellent clustering of samples within the same
Figure 1. Inhibition of target signaling pathways in cancer cells
following drug treatment. Schematic of signaling pathways
targeted by LY294002 and 17AAG and Western blots showing
modulation of p-4E-BP1 and c-Raf (b-actin as loading control) levels
following administration of DMSO (solvent control; C), LY294002 (L) or
17AAG (A).
doi:10.1371/journal.pone.0026155.g001
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treatment group and clear separation between the 3 different
treatment conditions (dimethyl sulfoxide (DMSO) as solvent
control, LY294002 and 17AAG), for both PC3 and LNCaP cell
lines. In light of the excellent separation indicated by the above
analyses and with the objective of gaining a better understanding
of the metabolic changes underlying the observed differences, we
repeated the PCAs, performing comparisons of the spectra
acquired on untreated (solvent control) samples versus those
obtained from either LY294002 or 17AAG treated samples for
each cell line. As expected, the scores plots obtained from these
PCAs (Fig. 3) indicate the complete separation of solvent control
and each of the treatments along the first principal component
(PC1). The advantage of this analysis resides in the fact that the
PC1 loadings plots capture the metabolic changes specifically
induced by the considered drug treatment (compared to control).
In fact, PC1 explains the large majority of the total variability
(between 63% and 77% depending on the cell line/treatment
considered), while PC2 explains less than 12% (between 9% and
12%) of the total variability.
The analysis of the loadings plots (Fig. 4) obtained from each
of the PCAs revealed discriminatory metabolites for the different
cell lines/treatments. Specifically, the loadings plots obtained
from the comparison of solvent control and LY294002 treatments
indicated the decrease of intracellular alanine, lactate, fumarate,
glutathione and phosphocholine concentrations following treat-
ment in both PC3 and LNCaP prostate cancer cells. The
administration of LY294002 also induced the accumulation of
branched amino acids (valine, leucine, isoleucine) and glutamine
in both prostate cancer cells. Some disparate changes among the
two prostate cancer cells were also observed, including the
decrease of taurine, myo-inositol and uridine diphosphate (UDP)-
glucose in PC3 cells and asparagine and glycine in LNCaP cells,
and the accumulation of glucose, glycine, phenylalanine, tyrosine
and histidine in PC3 cells and UDP-N-acetyl-glucosamine, UDP-
N-acetyl-galactosamine, creatine, phosphocreatine, choline, gly-
cerophosphocholine, taurine, myo-inositol and citrate in LNCaP
cells.
In the case of 17AAG treatment, a decrease in lactate, alanine,
fumarate and glutamine, and the intracellular accumulation of
valine, leucine, isoleucine, phosphocholine, myo-inositol, taurine
and citrate were observed in both PC3 and LNCaP cells. It is
worth noting that citrate represents the largest peak in the loadings
plot, Fig. 4B, for PC3 cells treated with 17AAG. This metabolite
was virtually undetected in untreated and LY294002-treated PC3
cells, but accumulated in substantial amounts following 17AAG
treatment, as depicted in Fig. 5.
Other metabolic changes induced by treatment with 17AAG
included the intracellular accumulation of glucose, glycine,
phenylalanine, tyrosine and hystidine in PC3 and accumulation
of creatine, phosphocreatine, choline and glycerophosphocholine
in LNCaP cells. Concurrently glutathione and UDP-glucose
decreased in PC3 and asparagine, glycine, UDP-N-acetyl-
glucosamine and UDP-N-acetyl-galactosamine decreased in
LNCaP cells. Interestingly, our results indicated that several
metabolic changes in response to treatment with LY294002 and
17AAG were common to both prostate cancer cells.
Targeted analysis of proton MR spectra of breast cancer
cells
MCF-7 cells were treated with 25 mM LY294002 or 3 mM
17AAG. Similarly to the prostate samples, these doses were
previously determined such that they induced inhibition of target
proteins and inhibition of cell growth [24,48].
To confirm the generality of our findings in prostate cells we
next conducted a targeted analysis of the metabolic consequences of
LY294002 and 17AAG treatment in the MCF-7 cells. We focused
on the common metabolic changes detected in the prostate
samples when using the untargeted approach and therefore
quantified the modulations in the intracellular levels of lactate,
alanine, fumarate, phosphocholine, glutamine and glutathione. In
complete agreement with the results reported above for the
prostate cells, treatment with LY294002 induced the decrease of
intracellular alanine, lactate, fumarate, glutathione and phospho-
choline in MCF-7 breast cancer cells. Similarly, the decrease of
lactate, alanine, fumarate and glutamine, and the accumulation of
phosphocholine induced by the 17AAG treatment in PC3 and
LNCaP cells was also confirmed in MCF-7 breast cancer cells.
Quantification of the main metabolic changes is summarized in
Figure 6.
Discussion
In this study we investigated the global metabolic effects
induced in PC3 and LNCaP prostate cancer cell lines through
the pharmacological intervention with LY294002, a PI3K
inhibitor, and 17AAG, an HSP90 chaperone-function inhibi-
tor. We characterized the metabolic fingerprints of the prostate
cancer cells with and without treatment using 1H MRS and
then determined the metabolic changes associated with
response to each treatment using a completely untargeted and
unbiased multivariate statistical approach (PCA). Our aim was
to identify the commonalities in the two cell lines of the
Figure 2. Multivariate statistical analysis of the MR spectra. Scores plots (PC1 vs PC2) obtained by performing PCA on the MR spectra
acquired on polar extracts (8 replicates per treatment condition) of (A) both PC3 and LNCaP cells, and individual (B) PC3 and (C) LNCaP prostate
cancer cells following a 48-hrs treatment with DMSO (solvent control, black), LY294002 (green) and 17AAG (red).
doi:10.1371/journal.pone.0026155.g002
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metabolic signatures associated with response to treatment for
each of the inhibitors. A common metabolic profile was
observed in our studies that indicates that several metabolites
are simultaneously modulated following treatment with each of
the inhibitors. Moreover, we also confirmed the generality of
the two treatment-specific metabolic signatures in a breast
cancer cell line (MCF-7).
When considering the two inhibitors, both LY294002 and
17AAG have the ability to affect signaling via the PI3K pathway,
as indicated by decreased p-4E-BP1 levels downstream of
mammalian target of rapamycin (mTOR). The results of the
metabolic profiling indicate that regardless of the inherently
different metabolic fingerprint and genetic background of the two
prostate and one breast cancer cell lines, changes in the metabolic
signatures induced by the drug treatments demonstrate common-
alities which are probably associated with the PI3K/Akt pathway
and downstream modulation of HIF-1a. Both drug treatments
induce the intracellular depletion of lactate and alanine in all 3 cell
lines. Lactate dropped between 30% and 65% after LY294002
treatment and between 17% and 35% after 17AAG treatment,
depending on the cell line. Alanine dropped between 20% and
50% with LY294002 and between 27% and 58% with 17AAG
depending on the cell line. These results points to hindered
glycolysis upon administration of the drug treatments and is
consistent with the known activation of glucose uptake and
glycolysis by PI3K/Akt signaling [49]. Intracellular fumarate also
decreased (between 43% and 72% with LY294002 and between
36% and 88% with 17AAG treatment) in all prostate and breast
cancer cells after the administration of either drug indicating that
it might be a key mediator of this response. In fact, it has been
previously reported that the inhibition of fumarate hydratase (FH)
and the associated accumulation of intracellular fumarate coincide
with HIF upregulation [50].
In contrast, other metabolites showed a ‘‘drug-specific’’
behavior. Phosphocholine dropped (13 to 50% depending on the
cell line) following PI3K inhibition but increased (between 10 and
83%) following HSP90 inhibition, in line with previous studies.
Phosphocholine was previously reported to decrease following
treatment with LY294002 and wortmannin (another PI3K
inhibitor; [22]) and increase following 17AAG treatment in
human breast and colon cancer cell lines [24,25].
The modulation of glutamine was also drug specific: it
increased (approximately 25% in the 2 prostate cancer cell lines)
or stayed constant following PI3K inhibition and dropped (20–
Figure 3. Multivariate statistical analysis of the MR spectra. Scores plots (PC1 vs PC2) obtained by performing PCA on the MR spectra
acquired on polar extracts (8 replicates per treatment condition) of PC3 and LNCaP prostate cancer cells. Control samples were compared to samples
treated for 48 hours with either LY294002 ((A) for PC3 and (C) for LNCaP cells) or 17AAG ((B) for PC3 and (D) for LNCaP cells).
doi:10.1371/journal.pone.0026155.g003
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30%) following HSP90 inhibition. To the best of our knowledge,
these findings have not been previously reported. Whereas
further studies are needed to fully understand the underlying
mechanism of these changes, these observations are in line with
the potentially fundamental role of glutaminolysis in cancer cell
growth and the molecular/metabolic links reported between Myc
and both glutaminase expression and glutamine-uptake regula-
tion [51–53].
The observation that the intracellular concentration of citrate
is increased following 17AAG treatment is highly significant in
the context of prostate cancer as it might indicate a specific shift
towards a more physiologic metabolism of prostate cancer cells.
Citrate is known to be physiologically present in large amounts
in the healthy prostate. However, citrate levels dramatically
drop upon development of prostate cancer. Although 17AAG
has not shown significant efficacy in a phase II clinical trial in
prostate cancer patients, it is possible that the use of this drug
combined with other agents would contribute to improving
outcome by mediating a normalization of metabolism in
prostate cancer cells.
In conclusion, this research highlights the potential of MRS-
based untargeted metabolomics. Using this approach we identified
a possible global metabolic signature associated with PI3K and
HSP90 inhibition. This study not only confirmed previous work
Figure 4. Multivariate statistical analysis of the MR spectra. Loadings plots (on PC1) obtained by performing the PCA comparisons on the MR
spectra of control and one treatment per analysis (as shown in Fig. 3) acquired on polar extracts of PC3 (black line) and LNCaP (red line) prostate
cancer cells following 48 hours of treatment with (A) LY294002 or (B) 17AAG. Enlarged sections of the loadings plots represent the region of 1.9–4.1
ppm. Ala: alanine; Asn: asparagine; Cho: choline; Cit: citrate; Cre: creatine; Fum: fumarate; Glc: glucose; Gln: glutamine; Gly: glycine; GPcho:
glycerophosphocholine; GSH: glutathione; His: histidine; Ile: isoleucine; Lac: lactate; Leu: leucine; m-Ino: myo-inositol; Pcho: phosphocholine; Pcre:
phosphocreatine; Phe: phenylalanine; Tau: taurine; Tyr: tyrosine; Val: valine, UDPS: UDP sugars.
doi:10.1371/journal.pone.0026155.g004
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but also identified previously unknown putative links between
signaling and metabolic pathways. Once individual metabolic
changes are validated through detailed mechanistic studies, a
combination of metabolic alterations could be envisaged which
would provide a more specific signature of response than single
metabolite biomarkers. Additional studies are under way in our
lab in animal xenograft models of breast and prostate cancer to
verify and validate in vivo the response signature to treatment with
PI3K and HSP90 inhibitors using high resolution magic angle
spinning (HR-MAS) MRS and MR spectroscopic imaging. The
potential value of HR-MAS MR analysis of tumor biopsies to
predict long-term survival and evaluate response to treatment has
been previously reported [54]. In the long term, knowledge of the
expected metabolic signature of response to targeted therapies
could lead to the development of automated decision-support tools
based on in vivo noninvasive patient MRS data similar to the
approach developed in the context of the INTERPRET project
(http://gabrmn.uab.es/INTERPRET) wherein the MRS signa-
ture is proposed as a tool to assist in the diagnosis and grading of
brain tumors and other abnormal brain masses [55,56].
Ultimately, this could lead to specific non-invasive methods for
monitoring response in the in vivo clinical setting.
Figure 5. Accumulation of citrate following treatment with
17AAG in PC3 prostate cancer cells. Enlarged section (2.49 – 2.72
ppm) of the MR spectra acquired on polar extracts of PC3 cells
following 48 hours of treatment with DMSO (solvent control, black),
LY294002 (green) and 17AAG (red). Spectra were normalized according
to the probabilistic quotient normalization method.
doi:10.1371/journal.pone.0026155.g005
Figure 6. Common metabolic changes in prostate and breast cancer cells following drug treatment. Quantification of selected
metabolites (shown as percent of control, mean 6 standard deviation) from MR spectra acquired on prostate (PC3 and LNCaP, N= 8) and breast
(MCF-7, N = 3) cancer cell lines following 48 hours of treatment with (A) LY294002 or (B) 17AAG. *: p,0.05; **: p,0.005; ***: p,0.0005. Pcholine:
phosphocholine.
doi:10.1371/journal.pone.0026155.g006
MRS Metabolomic Fingerprint of Treatment Response
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Materials and Methods
Cell culture and treatments
PC3, LNCaP (prostate) and MCF-7 (breast) cancer cell lines
were obtained from American Type Culture Collection via
University of California San Francisco (UCSF) Cell Culture
Facility (San Francisco, CA, USA) and were maintained in
exponential proliferation in Dulbecco’s Modified Eagle Medium
(DMEM) supplemented with 10% heat-inactivated fetal bovine
serum, 2 mM L-glutamine, 100 units ml21 of penicillin and
100 mg ml21 of streptomycin. The cells were cultured in a
humidified chamber at 37uC and with 5% CO2.
For all the experiments cells were incubated with drug for
48 hours as follows. PC3 cells with 25 mM LY294002 (PI3K
inhibitor) and 1 mM 17AAG (HSP90 inhibitor), LNCaP cells with
10 mM LY294002 and 0.25 mM 17AAG and MCF-7 cells with
25 mM LY294002 and 3 mM 17AAG. The treatment doses were
determined such that they decreased cell viability to approxi-
mately 50% of solvent control after 48 hours of treatment by
using the cell proliferation assay detailed below. All treatments
were performed with matching DMSO solvent control (1:1000
final concentration in culture medium) and were replenished after
24 hours.
Cell viability assay
The effect of different drug treatment doses on cell viability was
determined using the WST-1 reagent assay (Roche). Cells were
seeded in 96-well plates and treated for 4 to 48 hours with 4
different treatment doses for each drug. After treatment, WST-1
reagent was incubated in wells for approximately 1 hour and cell
viability was determined by spectrophotometric (Tecan) quantifi-
cation of absorbance at 440 nm.
Western Blotting
The effect of treatment with LY294002 and 17AAG on the
levels of target proteins was analyzed by Western blotting. Whole
cell lysates from treated and untreated cells were separated on 4%
to 20% SDS-PAGE gels (Bio-Rad). Proteins were then transferred
onto nitrocellulose membranes, blocked and incubated with
primary and secondary (anti-IgG horseradish peroxidase-linked,
Cell Signaling) antibodies. Primary antibodies against p-4E-BP1,
c-Raf and b-actin (as loading control) (Cell Signaling) were used.
Immunocomplexes were visualized using enhanced chemilumi-
nescence (ECL) Western Blotting Substrate (Pierce).
MR sample preparation
In all cases, cells were extracted using a dual phased extraction,
as described previously [29]. The extraction of MCF-7 breast
cancer cells (3 replicates) was previously described in detail
[24,48]. In the case of PC3 or LNCaP prostate cancer cells,
following 48 hour treatments, approximately 56106 cells were
washed twice with phosphate buffered saline (PBS) in the tissue
culture flask and then fixed using ice-cold methanol. Cells were
then scraped off and transferred with the methanol to a glass
centrifuge tube. Chloroform and water were then added to the
methanol in equal volumes (final solution 1:1:1 methanol:chlor-
oform:water). The solution was vortexed and centrifuged to
separate the aqueous and lipid phases. The two phases were then
collected separately and dried. The dried polar extracts (8
replicates per treatment per cell line) were then redissolved in
600 ml of 100 mM phosphate buffer (pH 7.0) prepared in 90%
H2O - 10% D2O and containing 0.5 mM sodium 3-(trimethylsi-
lyl)propionate-2,2,3,3-d4 (TMSP, Cambridge Isotope Laborato-
ries) as internal reference.
MR data acquisition and processing
One dimensional (1D) 1H MR spectra acquisition was
performed on the aqueous fraction of the PC3 and LNCaP cell
extracts using a 600 MHz spectrometer equipped with a
cryogenically cooled probe. 90u pulse and 4 s relaxation delay
were used and the water resonance was suppressed using
excitation sculpting [57]. The acquisition of 1H MR data from
MCF-7 cells extracts was previously described [24,48].
All the MRS datasets were processed using NMRLab [58] in
the MATLAB programming environment (The MathWorks,
Inc.). Following standard processing steps, spectra were aligned,
selected signals arising from residual solvents (water, methanol
and chloroform) and from TMSP were excluded. Spectra were
normalized according to the probabilistic quotient method [59].
Spectra acquired on PC3 and LNCaP cell samples were then
binned at approximately 0.0017 ppm and the generalized-log
transformation was applied prior to conducting the multivariate
statistical analysis [60]. Principal component analysis (PCA) of the
complete PC3 and LNCaP extract MRS datasets was carried out
using MATLAB. For all datasets, MRS resonances of metabolites
were assigned by comparison with spectra of standard com-
pounds (www.bml-nmr.org) and the peak integrals of selected
metabolites were calculated using ACD/Spec Manager version
9.15 software (Advanced Chemistry Development) for relative
quantification. Data are reported as mean values 6 standard
deviation. It should be noted that the MRS datasets were
acquired under slightly different conditions for the breast and the
prostate cancer samples. However, for each cell line the spectra of
treated samples were always acquired under the exact same
conditions as the matching control samples. The relative
quantifications (as percent change when treatment is compared
to control) are thereby unaffected by the differing acquisition
conditions. For the prostate cancer samples (N= 8 per treatment
condition and per cell line) statistical significance was determined
using a Mann-Whitney U test with p,0.05 considered signifi-
cant. For the breast cancer samples (N= 3) which were used to
confirm the trends observed in the prostate samples, statistical
significance was assessed using a one-sided Mann-Whitney U test
with p,0.05 considered significant.
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